Clinical Trials

A new collaboration leverages a vast cord blood bank and advanced AI to create off-the-shelf cell therapies, promising a new era in regenerative medicine.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

A new therapy programs immune cells inside the body to fight disease. Sail Biomedicines is pioneering this approach to offer a potential cure for autoimmunity.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

MeiraGTx will present 3-year data on a one-time therapy for radiation-induced dry mouth, a condition affecting millions of head and neck cancer survivors.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.